國(guó)際癌癥個(gè)體化創(chuàng)新醫(yī)學(xué)組織（Worldwide Innovative Networking in personalized cancer medicine, WIN）是一家由美國(guó)MD Anderson 癌癥中心和法國(guó)IGR （Institute Gustave Roussy）癌癥中心及17家國(guó)際知名癌癥中心共同發(fā)起的非盈利性機(jī)構(gòu)。該機(jī)構(gòu)的目標(biāo)旨在通過(guò)癌癥診療研究中心、醫(yī)藥研發(fā)和器械設(shè)備公司、政府機(jī)構(gòu)及病人團(tuán)體之間的合作，促進(jìn)腫瘤遺傳分子生物學(xué)標(biāo)記物的重大基礎(chǔ)研究成果向臨床應(yīng)用轉(zhuǎn)化，力爭(zhēng)在癌癥的早期診斷和個(gè)體化靶向治療領(lǐng)域取得突破性進(jìn)展來(lái)攻克腫瘤。
    現(xiàn)WIN向各成員單位征集研究和臨床項(xiàng)目。請(qǐng)有意申報(bào)者于5月15日前將填好的項(xiàng)目申報(bào)表（見(jiàn)附件）發(fā)送至國(guó)際事務(wù)部
具體要求如下：
Directorate of WIN has decided to launch a new call for research projects among our members.
The project/trial proposals should be fully aligned with the mission of WIN, which is to achieve rapid and efficient translation of ground breaking early diagnostic and personalized cancer medicine discoveries into the standards for clinical care, to significantly improve the outcomes and quality of life of cancer patients.
WIN provides access to diverse populations of patients who vary in genetic and cultural backgrounds. This is important in evaluating new biomarker and targeted therapies.
Proposals can address one of the following categories, or others:
? Cancer Detection/Early Diagnosis
? Prognostic Biomarkers
? Predictive Biomarkers for treatment selection
? Biomarkers for monitoring Disease
? Targeted therapy alone and in combinations
? Data mining
The projects/trials will be primarily evaluated for their originality, innovation and potential clinical impact.
Remember that each project/trial is Principal Investigator-initiated and will be sponsored and administered by the Principal Investigator’s institution and/or the other institutions that are participating. The proposal should provide a plan for securing funding of the clinical trial and companion laboratory studies. The proposal must include a description of planned grant applications including agency or commercial sponsor, planned submission date, anticipated funding date if successful and estimated budget. WIN Consortium’s role will be to help in planning the trial and assist the Principle Investigator in raising funds.
Proposals will be submitted for evaluation to the WIN Scientific Advisory Board by end of May. The SAB will have a first meeting to discuss the proposals’ evaluations during the WIN Symposium in Paris on July 12.
The proposals should be submitted in electronic format (tables or schema may be converted to .pdf format to assure accurate transfer) using the attached form  .
Each of the scientific sections should be sufficient to constitute the corresponding sections of a final protocol, but they should not be excessive or encyclopedic.